Raptor Pharmaceutical Corp. to Present at the 8th Annual BIO Investor Forum
27 Oktober 2009 - 12:00PM
PR Newswire (US)
Starting October 27th, the Company will use NASDAQ Ticker Symbol:
RPTP NOVATO, Calif., Oct. 27 /PRNewswire-FirstCall/ -- Raptor
Pharmaceutical Corp. (NASDAQ:RPTP), today announced that senior
management will present a corporate overview and update at the 8th
Annual BIO Investor Forum, to be held October 28-29, 2009 at the
Palace Hotel in San Francisco, CA. Raptor's presentation will take
place on Thursday, October 29 at 1:00pm in the Pacific Heights
room. (Logo:
http://www.newscom.com/cgi-bin/prnh/20071022/NYM074LOGO ) For more
information on BIO Investor Forum conference please visit:
http://investorforum.bio.org/opencms/bif/2009/index.jsp Separately
the company announced that as of Tuesday, October 27, Raptor will
transition from its temporary NASDAQ ticker symbol, RPTPD, to the
ticker symbol RPTP. Raptor was temporarily issued the NASDAQ ticker
symbol RPTPD following the completion of its merger with
TorreyPines Therapeutic which closed September 29, 2009. About
Raptor Pharmaceutical Corp. Raptor Pharmaceutical Corp.
(NASDAQ:RPTP) ("Raptor") is dedicated to speeding the delivery of
new treatment options to patients by working to improve existing
therapeutics through the application of highly specialized drug
targeting platforms and formulation expertise. Raptor focuses on
underserved patient populations where it can have the greatest
potential impact. Raptor currently has product candidates in
clinical development designed to potentially treat nephropathic
cystinosis, non-alcoholic steatohepatitis ("NASH"), Huntington's
Disease ("HD"), aldehyde dehydrogenase ("ALDH2") deficiency, and a
non-opioid solution designed to potentially treat chronic pain.
Raptor's preclinical programs are based upon bioengineered novel
drug candidates and drug-targeting platforms derived from the human
receptor-associated protein ("RAP") and related proteins that are
designed to target cancer, neurodegenerative disorders and
infectious diseases. For additional information, please visit
http://www.raptorpharma.com/. FORWARD LOOKING STATEMENTS This
document contains forward-looking statements as that term is
defined in the Private Securities Litigation Reform Act of 1995.
These statements relate to future events or our future results of
operation or future financial performance, including, but not
limited to the following statements: Raptor's ability to
successfully develop any of its product candidates. These
statements are only predictions and involve known and unknown
risks, uncertainties and other factors, which may cause the
Company's actual results to be materially different from these
forward-looking statements. Factors which may significantly change
or prevent the Company's forward looking statements from fruition
include that Raptor may be unsuccessful in developing any products
or acquiring products; that Raptor's technology may not be
validated as it progresses further and its methods may not be
accepted by the scientific community; that Raptor is unable to
retain or attract key employees whose knowledge is essential to the
development of its products; that unforeseen scientific
difficulties develop with the Company's process; that Raptor's
patents are not sufficient to protect essential aspects of its
technology; that competitors may invent better technology; that
Raptor's products may not work as well as hoped or worse, that the
Company's products may harm recipients; and that Raptor may not be
able to raise sufficient funds for development or working capital.
As well, Raptor's products may never develop into useful products
and even if they do, they may not be approved for sale to the
public. Raptor cautions readers not to place undue reliance on any
such forward-looking statements, which speak only as of the date
they were made. Certain of these risks, uncertainties, and other
factors are described in greater detail in the Company's filings
from time to time with the Securities and Exchange Commission (the
"SEC"), which Raptor strongly urges you to read and consider,
including the joint proxy statement/prospectus on Form S-4 filed
with the SEC on August 19, 2009; Raptor's annual report on Form
10-K filed with the SEC on March 27, 2009; Raptor's quarterly
report on Form 10-Q filed with the SEC on August 11, 2009; Raptor's
wholly-owned subsidiary's, Raptor Pharmaceuticals Corp. ("RPC")
Registration Statement on Form S-1, as amended, that was declared
effective on August 7, 2008; RPC's annual report on Form 10-K filed
with the SEC on October 30, 2008, as amended by that Form 10-K/A
filed with the SEC on December 23, 2008; and RPC's quarterly report
on Form 10-Q filed with the SEC on July 15, 2009, all of which are
available free of charge on the SEC's web site at
http://www.sec.gov/. Subsequent written and oral forward-looking
statements attributable to Raptor or to persons acting on its
behalf are expressly qualified in their entirety by the cautionary
statements set forth in Raptor's reports filed with the SEC. Raptor
expressly disclaims any intent or obligation to update any
forward-looking statements. For more information, please contact:
Karl Cahill, Investor Relations (858) 531-6100 The Ruth Group Sara
Ephraim Pellegrino (investors) (646) 536-7002 Janine McCargo
(media) (646) 536-7033
http://www.newscom.com/cgi-bin/prnh/20071022/NYM074LOGODATASOURCE:
Raptor Pharmaceutical Corp. CONTACT: Karl Cahill, Investor
Relations, +1-858-531-6100, ; or The Ruth Group, Sara Ephraim
Pellegrino (investors), +1-646-536-7002, , or Janine McCargo
(media), +1-646-536-7033, Web Site: http://www.raptorpharma.com/
Copyright